Impact of resistance to individual first-line and injectable drugs on adverse treatment outcome among patients with nonextensively drug-resistant (non-XDR) multidrug-resistant (MDR) tuberculosis (TB) or extensively drug-resistant (XDR) TB
| Treatment success | Adverse treatment outcome | Total | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | |
| MDR-TB (non-XDR) | 109 | 46 | 155 | ||
| Ethambutol | |||||
| Susceptible | 36 | 19 | 55 | 1 | 1 |
| Resistant | 73 | 27 | 100 | 0.70 (0.33–1.53) | 0.83(0.2–2.98)# |
| Pyrazinamide | |||||
| Susceptible | 48 | 24 | 72 | 1 | 1 |
| Resistant | 61 | 22 | 83 | 0.72 (0.34–1.53) | 0.68 (0.20–2.28)# |
| Streptomycin | |||||
| Susceptible | 75 | 30 | 105 | 1 | 1 |
| Resistant | 34 | 16 | 50 | 1.18 (0.53–2.58) | 1.05(0.30–3.70)# |
| Kanamycin | |||||
| Susceptible | 99 | 43 | 142 | 1 | 1 |
| Resistant | 10 | 3 | 13 | 0.69 (0.12–2.87) | 0.14 (0.01–2.63)¶ |
| Capreomycin/enviomycin | |||||
| Susceptible | 102 | 46 | 148 | 1 | 1 |
| Resistant | 7 | 0 | 7 | 0.24 (0.00–1.61)+ | 0.07 (0–1.01) #,+ |
| Ofloxacin | |||||
| Susceptible | 87 | 35 | 122 | 1 | 1 |
| Resistant | 22 | 11 | 33 | 1.24 (0.49–3.01) | 1.11 (0.22–5.50)# |
| XDR-TB | 23 | 19 | 42 | ||
| Ethambutol | |||||
| Susceptible | 2 | 4 | 6 | 1 | 1 |
| Resistant | 21 | 15 | 36 | 0.36 (0.03–2.94) | 0.56 (0.03–9.96)¶ |
| Pyrazinamide | |||||
| Susceptible | 8 | 2 | 10 | 1 | 1 |
| Resistant | 15 | 17 | 32 | 4.53 (0.72–48.68) | 5.28 (0.20–140.4)¶ |
| Streptomycin | |||||
| Susceptible | 12 | 3 | 15 | 1 | 1 |
| Resistant | 11 | 16 | 27 | 5.81 (1.14–38.0) | 12.05 (1.48–98.38)¶ |
| Kanamycin | |||||
| Susceptible | 2 | 1 | 3 | 1 | 1 |
| Resistant | 21 | 18 | 39 | 1.71 (0.08–106.7) | 1.71 (0.05–59.85)¶ |
| Capreomycin/enviomycin | |||||
| Susceptible | 12 | 13 | 25 | 1 | 1 |
| Resistant | 11 | 6 | 17 | 0.50 (0.12–2.10) | 0.14 (0.002–8.20) |
Data are presented as n, unless otherwise stated. OR: odds ratio; CI: confidence interval. #: adjusted for age, sex, body mass index (BMI), the presence of comorbidities, bilateral cavities, albumin levels, surgery and number of used drugs; ¶: adjusted for age, sex, the presence of comorbidities, bilateral cavities, albumin levels, surgery and number of used drugs, but not for BMI due to complete determination cases; +: OR was estimated using the exact logistic regression model.